Prostate specific antigen in black and white men after hormonal therapies for prostate cancer

Journal of Urology

Volumn 158, Issue 1, 1997, Pages 150-154

  Fowler Jr , Jackson E ^a   Bigler, Steven A ^a   Renfroe, D Land ^a   Dabagia, Mark D ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Hormones; Prostate specific antigen; Prostatic neoplasms; Racial stocks

Indexed keywords

FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DRUG WITHDRAWAL; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; METASTASIS; NEGRO; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE;

EID: 0030914629     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199707000-00047     Document Type: Article

References (22)

1. Miller, B. A., Ries, L. A. G., Hankey, B. F., Kosary, C. L., Harras, A., Devesa, S. S. and Edwards, B. K.: SEER Cancer Statistics Review: 1973-1990. National Institutes of Health Publication No. 93-2789. Bethesda, Maryland: National Cancer Institute, 1993.
2. Fowler, J. E., Jr., Pandey, P., Seaver, L. E., Feliz, T. P. and Braswell, N. T.: Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. J. Urol., 153: 1860, 1995.
3. American Joint Committee on Cancer: Manual for Staging of Cancer, 4th ed. Philadelphia: J. B. Lippincott Co., 1992.
4. Kuhn, J. M., Billebaud, T., Navratil, H., Moulonguet, A., Fiet, J., Grise, P., Louis, J. F., Costa, P., Husson, J. M. and Dahan, R.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). New Engl. J. Med., 321: 413, 1989.
5. Fowler, J. E., Jr., Pandey, P., Seaver, L. E. and Feliz, T. P.: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J. Urol., 154: 448, 1995.
6. Hortin, G. L., Bahnson, R. R., Daft, M., Chan, K. M., Catalona, W. J. and Ladenson, J. H.: Differences in values obtained with 2 assays of prostate-specific antigen. J. Urol., 139: 762, 1988.
7. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M. and Fossa, S. D.: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 11: 607, 1993.
8. Smith, J. A., Jr., Crawford, E. D., Lange, P. H., Lynch, D. F., Al-Juburi, A., Bracken, R. B., Wise, H. A. and deGery, A.: PSA correlation with response and survival in advanced carcinoma of the prostate. J. Urol., part 2, 149: 430A, abstract 868, 1993.
9. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radial prostatectomy treated patients. J. Urol., 141: 1076, 1989.
10. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
11. Fowler, J. E., Jr., Feliz, T. P., Pandey, P., Seaver, L. E. and Braswell, N. T.: Racial differences in the characteristics of prostate cancer at diagnosis. J. Urol., part 2, 153: 503A, abstract 1100, 1995.
12. Moul, J. W., Sesterhenn, I. A., Connelly, R. R., Douglas, T., Srivastava, S., Mostofi, F. K. and McLeod, D. G.: Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A., 274: 1277, 1995.
13. Davidson, P. J., Hop, W., Kurth, K. H., Fossa, S. D., Waehre, H., Schroder, F. H. and the European Organization for Research and Treatment of Cancer Genitourinary Group: Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to 4,N1 to 3.MO,D1). J. Urol., 154: 2118, 1995.
14. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., 152: 1821, 1994.
15. Fowler, J. E., Jr., Pandey, P., Braswell, N. T. and Seaver, L.: Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery, 116: 302, 1994.
16. Zagars, G. K. and von Eschenbach, A. C.: Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer, 72: 538, 1993.
17. Ross, R., Bernstein, L., Judd, H., Hanisch, R., Pike, M. and Henderson, B.: Serum testosterone levels in healthy young black and white men. J. Nat. Cancer Inst., 76: 45, 1986.
18. Ellis, L. and Nyborg, H.: Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids, 57: 72, 1992.
19. Eisenberger, M. A., Crawford, E. D., Wolf, M., Blumenstein, B., McLeod, D. G., Benson, R., Dorr, F. A., Benson, M. and Spaulding, J. T.: Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study: 0036. Sem. Oncol., 21: 613, 1994.
20. Optenberg, S. A., Thompson, I. M., Friedrichs, P., Wojcik, B., Stein, C. R. and Kramer, B.: Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. J.A.M.A., 274: 1599, 1995.
21. Fowler, J. E., Jr. and Terrell, F.: Survival in blacks and whites after treatment for localized prostate cancer. J. Urol., 156: 133, 1996.
22. Ibrahim, G. K., Coetzee, L. J. and Paulson, D. F.: Outcome of surgical therapy for clinically localized prostatic adenocarcinoma: caucasians and Afro-Americans. J. Urol., part 2, 153: 504A, abstract 1101, 1995.